A novel gyrB gene mutation in fluoroquinolone resistant clinical isolates of Mycobacterium tuberculosis

Singh, Pooja; Jain, Amita; Dixit, Pratibha; Prakash, Shantanu; Jaiswal, Indu; Venkatesh, Vimala; Singh, Mastan

doi:10.1186/1471-2334-14-s3-o14

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In M. tuberculosis, DNA gyrase is the sole target, since it lacks the topoisomerase (Nagaraja et al, 2017;Aubry, 2004) Fluoroquinolones are attractive since they have activity against replicating, non-replicating and intracellular M. tuberculosis. Resistance to fluoroquinolones in M. tuberculosis is due to mutations in DNA gyrase (Avalos et al, 2015); high level resistance is generally conferred by mutation in the GyrA subunit in the quinolone resistance determining region covering codons 74-113 (Soudani et al, 2010;Singh et al, 2015;Singh et al, 2021;Chaoui et al, 2018). A single mutation can lead to resistance to the entire class of fluoroquinolones, therefore novel agents with different binding modes would be useful.…”

Section: New Gyrase Inhibitorsmentioning

confidence: 99%

How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery

Bhagwat

Deshpande²,

Parish³

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Drug resistance is an increasing problem for the treatment of tuberculosis. The prevalence of clinical isolates with pre-existing resistance needs to be considered in any drug discovery program. Non-specific mechanisms of resistance such as increased efflux or decreased permeability need to be considered both in developing individual drug candidates and when designing novel regimens. We review a number of different approaches to develop new analogs and drug combinations or improve efficacy of existing drugs that may overcome or delay the appearance of clinical resistance. We also discuss the need to fully characterize mechanisms of resistance and cross- resistance to existing drugs to ensure that novel drugs will be clinically effective.

show abstract

Section: New Gyrase Inhibitorsmentioning

confidence: 99%

How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery

Bhagwat

Deshpande²,

Parish³

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

Clinical implication of novel drug resistance-conferring mutations in resistant tuberculosis

Mnyambwa

Kim

Ngadaya

et al. 2017

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Evolving novel and/or unfamiliar mutations are revolutionizing the pathways of antibiotic resistance of clinical tuberculosis. The accumulation and interaction of these poorly characterized mutations augment the complexity of resistant pathogenic strains and raise public health concerns. This article reviews our current understanding of the genetic changes that characterize drug resistance in tuberculosis and highlights the imperative for further investigations focusing on the effects of an individual mutation and interacting mutations with detailed strain epidemiology, particularly as these pertain to technology-limited countries with high tuberculosis incidence rates. Concomitantly, there is a need for the development, testing, and uptake of new tools for studying the effects of these mutations in drug resistance and fitness cost of the pathogen. Such genetic data are critical for effective localized and global tuberculosis control interventions and for accurate epidemiological predictions.

show abstract

Mutational analysis of gyrB at amino acids: G481A & D505A in multidrug resistant (MDR) tuberculosis patients

Mahmood

Abbas

Faraz

et al. 2019

Journal of Infection and Public Health

View full text Add to dashboard Cite

A novel gyrB gene mutation in fluoroquinolone resistant clinical isolates of Mycobacterium tuberculosis

Cited by 3 publications

References 0 publications

How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery

How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery

Clinical implication of novel drug resistance-conferring mutations in resistant tuberculosis

Mutational analysis of gyrB at amino acids: G481A & D505A in multidrug resistant (MDR) tuberculosis patients

Contact Info

Product

Resources

About